NEURVATI

As a Blackstone Life Sciences portfolio company, Neurvati is powered by best-in-class expertise, relentless passion, and deep resources to optimize the development of neuroscience therapeutics. We engage hand-picked strategic partners to broaden our reach while aligning ourselves with patient communities to enhance the development of treatments capable of transforming the lives of patients... Neurvati's first subsidiary company, GRIN Therapeutics, is developing an investigational product, radiprodil, as a novel therapy for patients diagnosed with GRIN-related disorders. GRIN-related disorders are genetically defined pediatric encephalopathies that present with a spectrum of symptoms, including epilepsy, behavioral disorders, autism, intellectual disability, and movement disorders. Radiprodil selectively targets receptors in the brain called NR2B receptors. NR2B receptors are overactive in the brains of GRIN2B-related disorder patients with gain-of-function mutations and are believed..